Spravato is intended for use only in a certified setting due to the dissociative components of the Spravato experience.
Spravato is self-administered under the direct observation of a licensed healthcare provider
Patients are monitored by a healthcare provider for at least 2 hours after each dose.
Spravato must never be dispensed directly to a patient for home use.
Certified pharmacies dispense Spravato only to certified healthcare settings.
No. Under the Spravato REMS, Spravato must never be dispensed directly to a patient for home use and is intended for use only in a certified healthcare setting.
Because Spravato can cause sedation and dissociation, and the REMS says patients must be monitored by a healthcare provider for at least 2 hours after administration.
No, it just means that there are careful requirements. It means the FDA requires specific safeguards so the benefits can outweigh the risks when Spravato is used for the right patient, in the right setting.
It can feel that way at first. “Spravato treamtent” (or Spravato treatment) is more structured than many medications because of REMS. In a certified Spravato site like Lumin Health, that structure is designed to be reassuring with time and familiarity.
Spravato is esketamine, a form related to ketamine, and it’s delivered under the FDA-mandated REMS. Many patients considering ketamine for depression compare Spravato with other ketamine therapy and ketamine treatment options based on safety, logistics, and fit.
Insurance coverage depends on the form of treatment. Spravato (esketamine) — the FDA-approved nasal spray for treatment-resistant depression — is often covered by insurances like the coverage you may have with your school or parents because it has a specific, recognized psychiatric indication. Coverage typically includes the medication, clinic administration, and monitoring, though patients may still have copays or deductibles. Ketamine in other forms — such as IV infusion, intramuscular injection, or oral lozenges — is used “off-label” for depression, meaning it’s not FDA-approved for that purpose. As a result, most insurers do not cover it, and treatment is usually paid for out of pocket. This difference is purely regulatory: the active drug in both Spravato and ketamine is chemically related, but only Spravato has undergone the approval process for psychiatric use. Some patients choose Spravato to access insurance benefits, while others prefer ketamine infusions for dosing flexibility or cost structure. At Lumin Health, we help people navigate both options so they can choose the path that best fits their clinical needs and financial circumstances.